返回 
加入收藏
4种治疗高脂血症中成药的临床综合评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 4种治疗高脂血症中成药的临床综合评价 |
| TITLE： | Clinical comprehensive evaluation of four Chinese patent medicines in the treatment of hyperlipidemia |
| 摘要： | 目的 评价血脂康、脂必泰、脂必妥、降脂灵4种治疗高脂血症的中成药的临床综合价值，为临床合理用药提供依据。方法基于证据与价值对决策的影响（EVIDEM）框架和《心血管病药品临床综合评价技术指南（2022年版试行）》，建立临床综合评价指标体系；检索中国知网、万方数据、维普网、PubMed、ScienceDirect、Embase及相关官网，收集4种中成药的药品说明书、指南/共识、系统评价/Meta分析等相关文献，从有效性、安全性、经济性、适宜性、可及性、创新性和中医药特色7个维度进行综合评价。结果指标体系包含7个一级指标、15个二级指标和30个三级指标。血脂康的综合评价得分最高，为81.4分，为Ⅰ类推荐；脂必泰为76.0分，脂必妥为60.9分，均为Ⅱ类推荐；降脂灵为48.8分，为Ⅳ类推荐。结论血脂康用于高脂血症的临床综合价值最优；脂必泰在安全性和中医药特色方面具有一定优势；脂必妥各方面表现较为均衡；降脂灵评分较低。临床可根据实际情况及患者特点选择适宜的药品。 |
| ABSTRACT： | OBJECTIVE To evaluate the clinical comprehensive value of four Chinese patent medicines （Xuezhikang， Zhibitai， Zhibituo， Jiangzhiling） in the treatment of hyperlipidemia， and provide a reference for rational clinical drug use. METHODS A clinical comprehensive evaluation index system was established in accordance with the Evidence and Value： Impact on Decision-Making （EVIDEM） framework and Technical Guideline for Clinical Comprehensive Evaluation of Cardiovascular Drugs （2022 edition， trial implementation）. CNKI， Wanfang data， VIP， PubMed， ScienceDirect， Embase and official websites were retrieved to collect the literature such as drug instructions， guidelines and consensus statements， and systematic reviews/meta-analyses for the four Chinese patent medicines. A comprehensive evaluation was conducted from seven dimensions： effectiveness， safety， economy， suitability， accessibility， innovation and characteristics of traditional Chinese medicine. RESULTS This evaluation index system included 7 first-level indicators， 15 second-level indicators and 30 third-level indicators. Xuezhikang achieved the highest comprehensive evaluation score of 81.4 points， and was classified as class Ⅰ recommendation. Zhibitai with 76.0 points and Zhibituo with 60.9 points were both classified as class Ⅱ recommendation. Jiangzhiling with 48.8 points was classified as class Ⅳ recommendation. CONCLUSIONS Xuezhikang demonstrates the optimal clinical comprehensive value for treating hyperlipidemia. Zhibitai exhibits certain advantages in terms of safety and characteristics of traditional Chinese medicine； Zhibituo shows a moderate performance in all aspects； Jiangzhiling has a relatively low score. Appropriate medicines can be selected clinically according to actual conditions and patients’ characteristics. |
| 期刊： | 2026年第37卷第06期 |
| 作者： | 张明珠；秦一卓；唐显帅；郑磊；宋金方 |
| AUTHORS： | ZHANG Mingzhu，QIN Yizhuo，TANG Xianshuai，ZHENG Lei，SONG Jinfang |
| 关键字： | 高脂血症；中成药；临床综合评价；血脂康；脂必泰；脂必妥；降脂灵 |
| KEYWORDS： | hyperlipidemia； Chinese patent medicine； clinical comprehensive evaluation； Xuezhikang； Zhibitai； Zhibituo； |
| 阅读数： | 0 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
